Abstract
When first introduced in 1992 the hepatitis A vaccine was recommended for individuals at high risk of exposure. This policy was not expected to have a significant impact on disease incidence at population level in view of the epidemiology of the hepatitis A virus (HAV).More recently two countries, Israel and Bahrain, and regions or subpopulations in others (Australia, China, Byelorussia, Italy, Spain, US) have embarked upon more ambitious vaccination programmes that aim to immunize whole birth cohorts. After a brief survey of the virology and epidemiology of HAV, the disease burden it inflicts and a short history of the development of HAV vaccines — both live (in China) and killed vaccines are available — the vaccination programmes introduced in the countries mentioned above are described. The results have been spectacular: disease incidence, not only in the vaccinated cohorts but also in the whole population, have plummeted within a few years of the start of mass vaccination. There is now convincing evidence that the vaccine confers herd immunity if the main spreaders of the virus are targeted for immunization. This finding should encourage other countries to start mass vaccination programmes against HAV, particularly as pharmacoeconomic studies are beginning to show that such a strategy could be a cost-effective way of controlling the disease. It is now even conceivable to eradicate HAV. In fact, this should be easier to achieve than polio eradication as HAV vaccines confer more durable immunity than polio vaccines. However, the global disease burden of HAV is generally thought not to be high enough to justify such an undertaking in the foreseeable future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Deinhardt F (1992) Prevention of hepatitis A: past, present and future. Vaccine 10(Suppl.1):S10–S14
Hilleman MR (1993) Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol 18(Suppl. 2):S5–S10
Hollinger FB, André FE, Melnick J (eds) (1992) Proceedings of International Symposiumon active immunization against hepatitis A. Vaccine 10(Suppl.1):S1–S176
André FE (1997) Hepatitis A vaccine: current status and future use. In:Proceedings of IX Triennial International Symposium on Viral Hepatis and Liver Disease. Rizetto M, Purcell RH, Gerin JL, Verne G (eds.). Minerva Medica, Rome, Italy, pp 624–626
André FE (2002) Randomised, cross-over controlled comparison of two inactivated hepatitis A vaccines. Vaccine 20:292–293
Mao JS, Dong DX, Zhang HY, et al. (1989) Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 159:621–624
André FE (1995) Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis 171(Suppl.1):S33–S39
Margolis HS, Shapiro CN (1992) Who should receive hepatitis A vaccine? Considerations for the development of an immunization strategy. Vaccine 10(Suppl.1):S85–S87
Committee for Safety of Medicines (1994) Hepatitis A vaccination (Havrix). Curr Prob Pharmacovigilance 20:16
Niu MT, Salive M, Krueger C, Ellenberg SS (1998) Two-year review of hepatitis Avaccine safety: data from the Vaccine Adverse Event Reporting System(VAERS). Clin Infect Dis 26:1475–1476
André FE, Van Damme P, Safary A, Banatvala J (2002) Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Exp Rev Vaccines 1(1):9–23
Jacobs RJ, Margolis HS, Coleman PJ (2000) The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 154(8):763–770
Ginsberg GM, Slater PE, Shouval D (2001) Cost-benefit of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 34:92–99
Chabot I, Goetghebeur MM, Grégoire J-P (2004) The societal value of childhood immunization. Vaccine 22:1992–2005
Melnick JL (1992) Properties and classification of hepatitis A virus. Vaccine 10(Suppl.1):S24–S26
Balayan MS (1992) Natural hosts of hepatitis Avirus. Vaccine 10(Suppl.1):S27–S31
Garin D, Biziagos E, Crance JM et al. (1996) Survival of infectious hepatitis A virus in mineral water and seawater. In: Proceedings of the International Symposium on enterically-transmitted hepatitis viruses. Buisson Y, Coursaget P, Kane M (eds). La Simarre, Tours, France pp 48–49
Halliday ML, Kang LY, Zhou TK, et al. (1991) An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 164:852–859
Favero MS, Bond WW (1998) Disinfection and sterilization. In:Zuckerman AJ, Thomas HC (eds) Viral Hepatitis: Scientific Basis and Clinical Management. New York, Alan R. Liss, pp 565–575
McCaustland GL, Bond WW, Bradley DW, et al. (1982) Survival of hepatitis A in feces after drying and storage for 1 month. J Clin Microbiol 16:957–958
Lemon SM, Jansen RW, Brown EA (1992) Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 10(Suppl.1):S40–S44
Lemon SM (1994) The natural history of hepatitis A: the potential for transmission by transfusion of blood and blood products. Vox Sang 67(Suppl.4):19–23
Tassapoulos NC, Papaevangelou GL, Ticehurst JR, et al. (1986) Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 154:231–237
Zuckerman AJ (1983) The history of viral hepatitis from antiquity to the present. In: Deinhardt F, Deinhardt J (eds.). Viral Hepatitis: Laboratory and Clinical Science. Marcel Decker, New York, pp 2–32
Gust G (1992) Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 10(Suppl.1):S56–S58
Banatvala J (1996) Epidemiology of hepatitis A (HAV) in Europe and its relationship to immunisation. In: Proceedings of the International Symposium on enterically-transmitted hepatitis viruses. Buisson Y, Coursaget P, Kane M (eds), La Simarre, Tours, France pp 72–77
Steffen R, Kane MA, Shapiro CN, et al. (1994) Epidemiology and prevention of hepatitis A in travelers. JAMA 272:885–889
Friedman MS, Blake PA, Koehler JE et al. (2000) Factors influencing a communitywide campaign to administer hepatitis A vaccine to men who have sex with men. Am J Public Health 90:1942–1946
Harkness J, Gildon B, Istre GR (1989) Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984–1987. Am J Public Health 79:463–466
Jacobson KH, Koopman JS. (2004) Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 132:1005–1022
Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS (2003) Regional variation in the cost-effectiveness of chilhood hepatitis A immunization. Pediatr Infect Dis J 22:904–914
WHO (2000) Weekly Epidemiol Rec 75:38–44
Armstrong GL, Bell BP (2002) Hepatitis A virus infection in the United States: model-based estimates and implications for childhood immunization. Pediatrics 209:839–845
CDC (2000) Hepatitis Surveillance Report No.57 38:1–31
Yao G (1991) Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In:Hollinger FB, Lemon SM, Margolis HS (eds). Viral Hepatitis and Liver Disease. Williams & Wilkins, Baltimore, pp 76–78
Ciocca M (2000) Clinical course and consequences of hepatitis A infection. Vaccine 18(Suppl.1):S71–S74
Reverbel da Silveira T, Ciocca M, Moreira-Silva SF et al. (2002) Hepatitis A as an etiological agent of acute liver failure in six Latin American countries. Presentation at 3rd World Congress of Pediatric Infectious Diseases, Santiogo, Chile, November 19–23, 2002
CDC (1999) MMWR 48:1–37
Kremastinou L, Kalapothaki V, Trichopoulos D (1984) the changing epidemiology of hepatitis A in urban Greece. Am J Epidemiol 120:703–706
André FE, D’Hondt E, Delem A, Safary A (1992) Clinical assessment of the safety and efficacy of an inactivated vaccine: rationale and summary of findings. Vaccine 10(Suppl.1):S160–S168
Van Herck K, Beutels P, Van Damme P et al. (2000) Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60(1):1–7
Van Damme P, Banatvala J, Fay O et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362:1065–1071
Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10(Suppl.1):S138–S141
Piazza M, Safary A, Vengente A et al. (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 17:585–588
Dagan R, Amir J, Mijalovsky A et al. (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibodies. Pediatr infect Dis J 19:1045–1052
Anderson RM, May RM (1985) Age-related changes in the rate of disease transmission: implications for the design of vaccination programme. J Hyg (Camb) 94:365–436
Fine PEM (2004) Community immunity. In: Vaccines, 4th ed. Plotkin SA, Orenstein WA (eds.) Elsevier, Philadelphia, pp 1443–1461
Miller M, Hinman AR (2004) Economic analyses of vaccine policies. In: Vaccines, 4th ed. Plotkin SA, Orenstein WA (eds.) Elsevier Inc., pp 1463–1490
Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS (1992) Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 10(Suppl.1) S59–S62
Bell BP, Shapiro CN, Alter MJ et al. (1998) The diverse patterns of hepatitis A in the United States-implications for vaccination strategies. J Infect Dis 178:1579–1584
World Health Organization (1992) Expanded Programme on Immunization global advisory group. Weekly Epidemiol Rec 3:11–16
Smith PF, Grabau JC, Wertzberger A, et al. (1997) The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 118:243–252
Gorkum J, Leenvaar-Kuijpers A, Kool JL, Coutinho RA (1998) Association between the yearly hepatitis A epidemic and travel behavior of children of immigrants in the four major cities of The Netherlands. Ned Tijdschr Geneesk 34: 1919–1923
Fine PEM (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15:265–302
Wertzberger A, Mench B, Kuter B et al. (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Eng J Med 327:453–457
Innis BL, Snitbhan R, Kunasol P et al. (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:28–34
Prikazsky V, Olear A, Cernoch A, Safary A, André FE. (1994) Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 44:457–459
McMahon BJ, Beller M, Williams J et al. (1996) A program to control an outbreak of hepatitis A by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150:733–739
Averhoff F, Shapiro C Hyams I et al. (1996) The use of inactivated hepatitis A vaccine to interrupt a communitywide hepatitis A outbreak. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington DC: American Society for Microbiogy 176: [Abstract H73].
Craig AS, Sockwell DC, Schaffner W et al. (1998) Use of hepatitis A vaccine in a communitywide outbreak of hepatitis A. Clin Infect Dis 27:531–535
Mele A, Stroffolini T, Palumbo F et al. (1997) Incidence of and risk for hepatitis A in Italy: Public health indications from a 10-year surveillance. J Hepatol 26:743–747
Lucioni C, Cipriani V, Mazzi S, Panunzio M (1998) Cost of an outbreak of hepatitis A in Puglia, Italy. Pharmacoeconomics 13:257–266
Mele A, Stroffolini T, Sagliocca L et al. (1997) Control of hepatitis B in Italy. In: Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rizetto M, Purcell RH, Gerin JL, Verne G (eds.). Minerva Medica, Rome, Italy pp 675–677
Lopalco PL, Salleras L, Barbuti S et al. (2001) Hepatitis A and B in children and adolescents — what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 19:470–474
Boccia D (2004) Community outbreak of hepatitis A in southern Italy-Campania, January–May 2004. Eurosurveillance Weekly 8(23): http://www.eurosurveillance.org/ew/2004/040603.asp
de la Torre J, Esteban R (1995) Implementing universal vaccination programmes: Spain. Vaccine 13(Suppl.1):S72–S74
Salleras L, Brugera M, Buti M, Dominguez A (2000) Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Vaccine 18(Suppl.1):S80–S82
Dominguez A, Salleras L, Carmona G, Batalla J (2003) Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21:698–701
Navas E, Salleras l, Gisbert R, Dominguez A, Prat A (2004) Economic evaluation of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the universal hepatitis B vaccination programme of preadolescents in schools. Fourth World Congress on Vaccines and Immunization in Tokyo, Japan, September 30–October 3 2004 [Abstract S1–S10]
Hanna JN, Hills SL, Humphreys JL (2004) Impact of hepatitis A vaccination of Indigenous Children on notifications of hepatitis A in North Queensland. Med J Aus 181:482–485
Merritt A, Symons D, Griffiths M (1999) The epidemiology of acute hepatitis A in North Queensland, 1996–1997. Commun Dis Intell 23:120–124
Hanna JN, Warnock TH, Shepherd RW, Selvey LA (2000) Fulminant hepatitis A in Indigenous children in North Queensland. Med J Aus 172:19–21
Zamir C, Rishpon D, Zamir D, Leventhal A, Rimon N, Ben-Porath E (2001) Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis 20:185–187
Dagan R, Leventhal A, Anis E, Slater P, Shouval D (2002) National hepatitis Avirus (HAV) immunization program aimed exclusively at toddlers in an endemic country resulting in >90% reduction in morbidity rate in all ages. 40th Annual Meeting of Infectious Diseases Society of America [Abstract 825]
Shouval D (2004) Universal immunization against hepatitis A to toddlers in Israel is leading to disappearance of HAV infection — The Jerusalem experience. Proceedings Biennial Scientific Meeting of International Association for Study of the Liver, Bahia, Brazil 4;4–5
Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D (2005) Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294:202–210
CDC (1996) Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 45(RR-15):1–30
CDC (1999) Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48(RR-12):1–37
Bialek SR, Thoroughman DA, Hu D et al. (2004) Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990–2001. Am J Public Health 94:996–1001
Samandari T, Bell BP, Armstrong GL (2004) Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 22:4342–4350
Van Effelterre T, Zink TK, Rosenthal P (2005) A model of hepatitis A transmission in the US. Poster 19 at Conference of American College of Preventive Medicine held on February, 16–20, Washington DC
Jacobs RJ, Zink T, Meyerhoff AS (2004) Hepatitis A immunization strategies: universal versus targeted approaches. Proceedings annual Meeting of Pediatric Academic Societies, San Francisco, May 1–4
CDC (2005) Hepatitis A vaccination coverage among children aged 24–35 months, United States, 2003. MMWR 54:141–144
CDC hepatitis A slide set. (http://www.cdc.gov)
Wasley A, Samandari T, Bell BP (2005) Incidence of hepatitis A in the United States in the era of vaccination. JAMA 294:194–201
Samoilovich EO (2005) Personal communication. March 2nd 2005
Anonymous (1992) Prospects for control of hepatitis A: panel discussion. In: Hollinger FB, André FE, Melnick J (eds). Proceedings of International Symposium on active immunization against hepatitis A. Vaccine 10(Suppl.1):S170–S174
Bell BP, Feinstone SM(2004) Hepatitis A vaccine. In: Vaccines, 4th ed. Plotkin SA, Orenstein WA (eds.) Elsevier Inc., pp 269–297
Scheifele DW (2005) Hepatitis A vaccines: the growing case for universal immunization of children. Expert Opin Pharmacother 6:157–164
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
André, F.E. (2006). Universal Mass Vaccination Against Hepatitis A. In: Plotkin, S.A. (eds) Mass Vaccination: Global Aspects — Progress and Obstacles. Current Topics in Microbiology and Immunology, vol 304. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-36583-4_6
Download citation
DOI: https://doi.org/10.1007/3-540-36583-4_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-29382-8
Online ISBN: 978-3-540-36583-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)